This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Intended Consequences

NEW YORK ( TheStreet) -- Biotechnology companies are basking in a valuation bubble, with many initial public offerings being expanded and oversubscribed and share prices soaring in first-day trading. But other changes in the business environment are gaining momentum that could put pressure on these companies' valuations, notably market forces resulting from health reform.

Several trends, most of them nudged forward by President Obama's Affordable Care Act, are coalescing and point to pressures on drug companies to lower the prices they charge consumers for pharmaceuticals. One of the goals of ACA is to decrease the cost of healthcare. Putting pressure on outrageously priced drugs is one way the law aims to do that. The result of that pressure could be declines in profit from new drugs.

The reasons are easy to see. Health care costs are shifting to consumers at a faster rate than ever before, and with the opening of the health care exchanges Oct. 1, higher deductibles and copays are becoming more the norm rather than the exception. The most affordable of those plans have high deductibles and copays.

Additionally, expenditures in consumer-directed health plans, or CDHPs, have grown at a slower rate than other types of plans, according to a recent survey of employers by benefits consultant Aon Hewitt. Such plans have higher deductibles and copays, paid by the employee through a personal fund, which grows every payday through pre-tax contributions. Indeed, consumer-directed health plans could be the most common type of coverage offered by companies with 500 or more workers in the next three to five years. In its annual survey of over 800 large and mid-size employers in the U.S., Aon Hewitt found that 56% now offer CDHPs. Another 30% said they're considering offering one in the next three to five years. At present, 10% offer a CDHP as the only option and 44% are thinking about making it the only choice.

Just at a time when consumers are having to bear more of the freight for healthcare costs, scientific advances, especially in gene-based drug discovery, have allowed biotech and pharmaceutical companies to develop personalized biologics, therapeutic vaccines and targeted small molecule drugs that work better than ever, but carry ultra-high price tags.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACOR $25.69 -5.52%
VRTX $82.16 -1.01%
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs